Research Analysts’ Weekly Ratings Updates for Agios Pharmaceuticals (AGIO)

Several analysts have recently updated their ratings and price targets for Agios Pharmaceuticals (NASDAQ: AGIO):

• 12/1/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Agios Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $38.00 price target on the stock.
• 11/26/2025 – Agios Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $38.00 price target on the stock.
• 11/25/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Agios Pharmaceuticals was given a new $32.00 price target on by analysts at Truist Financial Corporation.
• 11/24/2025 – Agios Pharmaceuticals is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $32.00 price target on the stock.
• 11/22/2025 – Agios Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/21/2025 – Agios Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $37.00 to $20.00. They now have a “neutral” rating on the stock.
• 11/20/2025 – Agios Pharmaceuticals was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
• 11/20/2025 – Agios Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $56.00 to $48.00. They now have a “buy” rating on the stock.
• 11/20/2025 – Agios Pharmaceuticals had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $40.00 to $25.00. They now have a “neutral” rating on the stock.
• 11/20/2025 – Agios Pharmaceuticals had its price target lowered by analysts at Bank of America Corporation from $54.00 to $32.00. They now have a “buy” rating on the stock.
• 11/20/2025 – Agios Pharmaceuticals was upgraded by analysts at Leerink Partners from a “market perform” rating to an “outperform” rating. They now have a $34.00 price target on the stock, down previously from $40.00.
• 11/19/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Agios Pharmaceuticals was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating. They now have a $28.00 price target on the stock, down previously from $57.00.
• 11/13/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Agios Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/7/2025 – Agios Pharmaceuticals was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d)” rating.
• 11/4/2025 – Agios Pharmaceuticals was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 3,302 shares of the business’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the sale, the insider directly owned 61,727 shares in the company, valued at approximately $2,711,049.84. The trade was a 5.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Cecilia Jones sold 3,651 shares of the firm’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $36.77, for a total value of $134,247.27. Following the completion of the transaction, the chief financial officer owned 33,870 shares in the company, valued at approximately $1,245,399.90. This trade represents a 9.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 7,553 shares of company stock valued at $305,001. 4.30% of the stock is owned by insiders.

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.